OncoMatch/Clinical Trials/NCT06474468
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer
Is NCT06474468 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies SHR-A2102；Adebrelimab；Cisplatin for advanced or metastatic esophageal cancer.
Treatment: SHR-A2102；Adebrelimab；Cisplatin — The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with Adebrelimab with or without other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer. To explore the reasonable dosage of SHR-A2102 for Advanced or Metastatic Esophageal Cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: antitumor therapy
antitumor therapy was received 4 weeks before the start of the study
Cannot have received: antibody-drug conjugate containing topoisomerase I inhibitor
previously received antiboy-coupled drugs containing topoisomerase I inhibitors
Cannot have received: systemic antitumor therapy
Systemic antitumor therapy was received 4 weeks before the start of the study
Cannot have received: radiation therapy
Perform non-chest radiation therapy with >30Gy within 28 days before dosing, chest radiation therapy with >30Gy within 24 weeks before first dosing, and radiation therapy with ≤30Gy within 14 days before first dosing
Lab requirements
Blood counts
Good level of organ function
Kidney function
Good level of organ function
Liver function
Good level of organ function
Good level of organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify